Trial of Autologous, Hapten-Modified Vaccine in Patients With Stage III or IV Melanoma

NCT00257465 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

82

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

BIOLOGICAL: Autologous, DNP-modified vaccine (M-Vax)
BIOLOGICAL: Autologous, DNP-Modified Melanoma Vaccine
BIOLOGICAL: Autologous, DNP-Modified Vaccine
BIOLOGICAL: Autologous, DNP-Modified Vaccine
BIOLOGICAL: Autologous, DNP-Modified Vaccine

Sponsor

AVAX Technologies